Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous (s.c.) infusions. Bioavailability was 99%+/-18% after s.c. administration, but peaks were reduced by about (43+/-29 versus 115+/-28 microg/ml) and times to peak were delayed. Simulations based on unbound concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval, suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2812167 | PMC |
| http://dx.doi.org/10.1128/AAC.00836-09 | DOI Listing |
Publication Analysis
Top Keywords
pharmacokinetics ertapenem
8
intravenous subcutaneous
8
subcutaneous infusions
8
ertapenem intravenous
4
infusions patients
4
patients steady-state
4
steady-state pharmacokinetics
4
ertapenem compared
4
compared patients
4
patients 1-g
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!